Elanco Acquires Prevtec Microbia

Merck Animal Health to acquire Elanco's aqua business for ~$1.3B

February 6, 2024

Veterinary

Merck Animal Health has agreed to buy Elanco Animal Health's aqua business for approximately US$1.3 billion in cash. The divestiture — which includes marketed brands, R&D projects, manufacturing sites in Prince Edward Island (Canada) and Dong Nai (Vietnam), and roughly 280 commercial and manufacturing employees — will allow Elanco to focus on higher-growth pet and livestock markets and use proceeds to pay down debt.

Merck Animal Health Acquires Vence

September 22, 2022

Agriculture

Merck Animal Health agreed to acquire Vence, a developer of virtual fencing and livestock management technology, from Vence's founders and shareholders. The acquisition (terms undisclosed) expands Merck Animal Health's animal intelligence and precision livestock management capabilities and was expected to close in the third quarter of 2022.

Dechra Pharmaceuticals to Acquire Invetx

July 18, 2024

Biotechnology

Dechra Pharmaceuticals Limited has agreed to acquire Boston-based Invetx Inc., a developer of species-specific monoclonal antibody therapeutics for companion animals, for up to $520 million on a cash-free, debt-free basis, subject to customary approvals. The deal gives Dechra access to Invetx's pipeline and half-life extension platform to expand its specialty veterinary biologics capabilities.

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Biotechnology

Sanofi will acquire clinical-stage biopharmaceutical company Vicebio in a deal worth up to $1.6 billion, including $1.15 billion upfront and $450 million in milestone payments. Vicebio, created by Medicxi using the University of Queensland's Molecular Clamp technology, develops multivalent vaccines targeting respiratory viruses and recently advanced a bivalent RSV/hMPV candidate into Phase 1 trials.

Eli Lilly Acquires Prevail Therapeutics

December 15, 2020

Biotechnology

Eli Lilly agreed to acquire Prevail Therapeutics for $22.50 per share in cash (approximately $880 million) plus a non-tradable contingent value right (CVR) worth up to $4.00 per share (up to ~$160 million), for total consideration of up to ~$1.04 billion. The deal establishes a gene therapy program at Lilly anchored by Prevail’s AAV9-based neuroscience pipeline; the transaction was structured as a tender offer with expected close in Q1 2021 subject to customary conditions.

PrevTech Innovations Acquires Agrivolt

January 12, 2024

Electrical Services

PrevTech Innovations has acquired Agrivolt, combining PrevTech’s electrical safety monitoring capabilities with Agrivolt’s stray-voltage detection and mitigation products to offer integrated electrical-safety solutions for the agricultural sector. The deal brings together complementary technologies and expertise to improve prevention, animal welfare, and electrical network resilience on farms across North America.